(thirdQuint)Eight-Week Efficacy & Safety Study of Brisdelle (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms Associated With Menopause.

 Eligible subjects will be entered into a 1-week observation period followed by a 1-week run-in period.

 Following completion of the run-in period, eligible subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.

5 mg or placebo in a 1:1 ratio.

 Study drug will be administered once daily at bedtime.

 Symptom assessment questionnaires will be administered at baseline and at Day 28 and Day 57 visits.

.

 Eight-Week Efficacy & Safety Study of Brisdelle (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms Associated With Menopause@highlight

This is an exploratory 8-week, multicenter, double-blind, randomized, placebo-controlled study of Brisdelle (paroxetine mesylate) Capsules 7.

5 mgin subjects with moderate to severe postmenopausal vasomotor symptoms (VMS), defined as follows: - Moderate VMS: Sensation of heat with sweating, able to continue activity - Severe VMS: Sensation of heat with sweating, causing cessation of activity